Filing Flows › Lipocine (LPCN) › Q1 2025
Lipocine (LPCN) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Lipocine (LPCN) reported revenue of $94K for the first quarter 2025 (Q1 2025), -99% from a year earlier and -97% from the quarter before.
Lipocine, Q1 2025: revenue $94K (-99% year over year), net loss $1.9M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $94K | -97% | -99% |
| Operating profit | −$2.1M | — | — |
| Net earnings | −$1.9M | — | — |
| Operating cash flow | −$2.0M | — | — |
What changed
Revenue was $94K in Q1 2025, down 99% year over year and down 97% from the previous quarter.
Operating costs exceeded revenue by $2.1M, an operating margin of -2226.8%. Total costs fell 50% while revenue fell 99%. The quarter ended with a net loss of $1.9M, after a profit of $1.8M the previous quarter.
Operating cash flow was −$2.0M. Non-cash charges added back $16K of depreciation and amortization and $71K of share-based compensation. Working capital and other items used $191K.
Questions
What was Lipocine's revenue in the first quarter 2025?
Lipocine (LPCN) reported revenue of $94K for the first quarter 2025 (Q1 2025), -99% from a year earlier and -97% from the quarter before.
Source: Lipocine 10-Q on SEC EDGAR.